From: Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review
Ā | Trial | Sample size | Rate of exclusion (%) | Infections Community/nosocomial | Pneumonia | PCT assay | Minimum duration AB therapy | Decision to start antibiotics (no AB), PCT/control | Duration of antibiotic therapy, PCT/control, days | Overruling PCT algorithm (%) | LOS ICU, PCT/control, days | Superinfection, PCT/control, N(%) | Relapse, PCT/control, N(%) | Mortality 28d, PCT/control, N(%) | Mortality 60d, PCT/control, N(%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Svoboda, 2007 [43] | Ā | 72 | 381 (84) | 0/72 | NA | PCT-Q | Ā | Ā | Ā | Ā | 16.1 Ā± 6.9/19.4 Ā± 8.9 | Ā | Ā | 10/38 (26 %)/13/34 (38 %) | Ā |
Nobre, 2008 [41] | ProSEP | 79 | 203 (72) | 53/26 | 52 | TRACE | Ā | Ā | 8 (4ā27)/14 (6ā39) | 19 | 4 (1ā21)/7 (1ā91) | 7/31 (22.5 %)/11/37 (29.7 %) | 1/39 (2.6 %)/1/40 (2.5 %) | 8/39 (20.5 %)/8/40 (20 %) | Ā |
Schroeder, 2009 [44] | Ā | 27 | 98 (78) | 0/27 | 8 | PCT LIA | yes | Ā | 6.6 Ā± 1.1/8.3 Ā± 0.7 | Ā | 16.4 Ā± 8.3/16.7 Ā± 5.6 | Ā | Ā | 3/14 (21.4 %)/3/13 (23.1 %) | Ā |
Stolz, 2009 [45] | ProVAP | 101 | 63 (38) | 0/101 | 101 | TRACE | yes | Ā | 10 (6ā16)/15 (10ā23) | 16 | 13 (7ā21)/13.5 (8ā22.2) | 7/51 (13.7 %)/6/50 (12 %) | Ā | 8/51 (16 %)/12/50 (24 %) | Ā |
Hochreiter, 2009 [46] | ProSICU | 110 | 285 (72) | 0/110 | 43 | PCT LIA | Ā | Ā | 5.9 Ā± 1.7/7.9 Ā± 0.5 | Ā | 15.5 Ā± 12.5/17.7 Ā± 10.1 | Ā | Ā | 15/57 (26.3 %)/14/53 (26.4 %) | Ā |
Bouadma, 2010 [42] | PRORATA | 601 | 685 (52) | 326/275 | 394 | TRACE | yes | 4 (1.7 %)/15 (4.8 %) | 10.3 Ā± 7.7/13.3 Ā± 7.6 | 53 | 15.9 Ā± 16.1/14.4 Ā± 14.1 | 106/307 (34.5 %)/97/314 (30.9 %) | 20/307 (6.5 %)/16/314 (5.1 %) | 65/307 (21.2 %)/64/314 (20.4 %) | 92/307 (30 %)/82/314 (26.1 %) |
Jensen, 2011 [47] | PASS | 1200 | 3 (0.3) | 480/720 | 666 | TRACE | Ā | Ā | 6 (3ā11)/4 (3ā10) | 17.9 | 6 (3ā12)/5 (3ā11) | Ā | Ā | 190/604 (31.5 %)/191/596 (32 %) | 231/604 (38.2 %)/220/596 (36.9 %) |